2026 年 03 月 02 日 行业日报 看好/维持 医药 医药 太平洋医药日报（20260302）：多肽药 Yuviwel 获 FDA 批准上市 ◼ 走势比较 (10%) (2%) 6% 14% 22% 30% 25/3/3 25/5/14 25/7/25 25/10/5 25/12/16 26/2/26 ◼ 子行业评级 | 化学制药 | 无评级 | | --- | --- | | 中药生产 | 无评级 | | 生物医药Ⅱ | 中性 | | 其 他 医 药 医 | 中性 | | 疗 | | 相关研究报告 代疗法 Loargys 获 FDA 批准>>-- 2026-02-26 证券分析师：周豫 <<太平洋医药日报（20260227）： Zongertinib 获 FDA 加速批准>>-- 2026-03-01 <<太平洋医药日报（20260226）：礼来 塞普替尼三期临床成功>>--2026- 02-27 <<太平洋医药日报（20260225）：酶替 电话： E-MAIL：zhouyua@tpyzq.com 分析师登记编号：S1190523060002 证券分析师：张崴 电话： E-MAIL：zhangwe ...

2026 年 02 月 25 日 行业日报 看好/维持 医药 医药 太平洋医药日报（20260225）：酶替代疗法 Loargys 获 FDA 批准 ◼ 走势比较 (10%) (2%) 6% 14% 22% 30% 25/2/25 25/5/9 25/7/21 25/10/2 25/12/14 26/2/25 ◼ 子行业评级 | 化学制药 | 无评级 | | --- | --- | | 中药生产 | 无评级 | | 生物医药Ⅱ | 中性 | | 其 他 医 药 医 | 中性 | | 疗 | | 相关研究报告 <<太平洋医药日报（20260224）： Molbreevi 获 FDA 授予优先审评资 格>>--2026-02-25 <<太平洋医药日报（20260213）：安进 Inebilizumab 获欧盟批准>>--2026- 02-15 <<太平洋医药日报（20260212）：默沙 东 Keytruda 获 FDA 批准新适应症>>- -2026-02-15 证券分析师：周豫 电话： E-MAIL：zhouyua@tpyzq.com 分析师登记编号：S1190523060002 电话： E-MAIL：zha ...

2026 年 02 月 24 日 行业日报 看好/维持 医药 医药 太平洋医药日报（20260224）：Molbreevi 获 FDA 授予优先审评资 格 ◼ 走势比较 (10%) (2%) 6% 14% 22% 30% 25/2/24 25/5/8 25/7/20 25/10/1 25/12/13 26/2/24 ◼ 子行业评级 | 化学制药 | 无评级 | | --- | --- | | 中药生产 | 无评级 | | 生物医药Ⅱ | 中性 | | 其 他 医 药 医 | 中性 | | 疗 | | 相关研究报告 <<太平洋医药日报（20260213）：安进 Inebilizumab 获欧盟批准>>--2026- 02-15 <<太平洋医药日报（20260212）：默沙 东 Keytruda 获 FDA 批准新适应症>>- -2026-02-15 <<太平洋医药日报（20260211）：礼来 米吉珠单抗在华获批新适应症>>-- 2026-02-13 证券分析师：周豫 电话： E-MAIL：zhouyua@tpyzq.com 分析师登记编号：S1190523060002 证券分析师：张崴 电话： E-MAIL： ...

Investment Rating - The industry rating is neutral, indicating that the overall return is expected to be between -5% and 5% relative to the CSI 300 index over the next six months [9]. Core Insights - AbbVie has submitted regulatory applications for its JAK inhibitor Rinvoq for the treatment of non-segmental vitiligo to both the FDA and EMA, based on positive results from the Phase 3 Viti-Up clinical study [5]. - The pharmaceutical sector showed a slight increase of +0.18% on February 5, 2025, outperforming the CSI 300 index by 0.78 percentage points, ranking 8th among 31 sub-industries [4]. - Among sub-industries, hospitals (+0.81%), offline pharmacies (+0.74%), and medical R&D outsourcing (+0.49%) performed well, while other bioproducts (-0.99%), vaccines (-0.44%), and pharmaceutical distribution (-0.25%) lagged behind [4]. Sub-industry Summary - Chemical pharmaceuticals: No rating [3] - Traditional Chinese medicine production: No rating [3] - Biopharmaceuticals II: Neutral [3] - Other pharmaceutical industries: Neutral [3]

2026 年 01 月 29 日 行业日报 看好/维持 医药 医药 太平洋医药日报（20260129）：Immix 在研 NXC-201 获 FDA 突破 性疗法认定 ◼ 走势比较 (10%) 0% 10% 20% 30% 40% 25/2/5 25/4/17 25/6/27 25/9/6 25/11/16 26/1/26 ◼ 子行业评级 | 化学制药 | 无评级 | | --- | --- | | 中药生产 | 无评级 | | 生物医药Ⅱ | 中性 | | 其 他 医 药 医 | 中性 | | 疗 | | 相关研究报告 <<太平洋医药日报（20260128）：罗氏 减重疗法 CT-388 二期临床成功>>-- 2026-01-28 <<太平洋医药日报（20260127）： Sarepta 基因疗法 Elevidys 三期临 床成功>>--2026-01-28 <<太平洋医药日报（20260126）：英矽 智能 ISM8969 获 FDA 批准临床>>-- 2026-01-27 证券分析师：周豫 电话： E-MAIL：zhouyua@tpyzq.com 分析师登记编号：S1190523060002 证券分析师 ...

Investment Rating - The industry rating is neutral, indicating that the overall return is expected to be between -5% and 5% relative to the CSI 300 index over the next six months [9]. Core Insights - Sarepta's gene therapy Elevidys has shown positive results in its Phase 3 clinical trial, maintaining higher than baseline scores in the North Star Ambulatory Assessment (NSAA) after three years in patients treated at an average age of 9 [5]. - The pharmaceutical sector experienced a decline of 1.11% on January 27, 2025, underperforming the CSI 300 index by 1.08 percentage points, ranking 27th among 31 sub-industries [4]. - Among sub-industries, other biological products (+0.13%) and in vitro diagnostics (-0.07%) performed well, while vaccines (-3.55%) and offline pharmacies (-2.69%) lagged [4]. Sub-industry Summary - Chemical Pharmaceuticals: No rating [3] - Traditional Chinese Medicine: No rating [3] - Biopharmaceuticals II: Neutral [3] - Other Pharmaceutical Industries: Neutral [3]

Investment Rating - The overall industry investment rating is neutral, with specific sub-industry ratings as follows: Chemical Pharmaceuticals - No rating, Traditional Chinese Medicine - No rating, Biopharmaceutical II - Neutral, Other Pharmaceuticals - Neutral [3][9] Core Insights - The pharmaceutical sector experienced a slight increase of +0.29% on January 26, 2025, outperforming the CSI 300 index by 0.19 percentage points, ranking 8th among 31 sub-industries in the Shenwan classification. Notable performers included vaccines (+7.99%), in vitro diagnostics (+3.73%), and blood products (+3.47%), while hospitals (-2.01%), medical R&D outsourcing (-1.36%), and offline pharmacies (-1.18%) lagged behind [4][5] - Recently, the company InSilico Medicine announced that its oral NLRP3 inhibitor ISM8969 received FDA approval for clinical trials aimed at treating Parkinson's disease. The upcoming Phase I trial will assess the safety, tolerability, and pharmacokinetics of ISM8969 in healthy volunteers, highlighting its potential to modulate pathological inflammatory responses in neurodegenerative diseases [5] - Ji'an Medical (002432) expects a net profit of 2.02-2.35 billion yuan for 2025, representing a year-on-year growth of 21.05%-40.83%. Meanwhile, Sangfor Health (688336) anticipates a revenue of 4.2 billion yuan, a 251.76% increase, and a net profit of 2.9 billion yuan, reflecting a 311.35% growth [6]

Core Insights - Adidas reported a 7% year-on-year revenue growth for FY2025H1, reaching €12.105 billion, with a net profit increase of 121% to €798 million [4] - The brand's revenue growth was 14% on a currency-neutral basis, with all regional markets achieving double-digit growth [4] - The company maintains its full-year guidance, expecting high single-digit revenue growth on a currency-neutral basis for FY2025, with double-digit growth for the Adidas brand [4] Market Trends - The domestic market indices showed positive performance, with the Shanghai Composite Index closing at 3,617.60, up 0.96% [3] - The textile and apparel sector experienced a decline of 2.14% this week, underperforming the broader market [5] - Retail sales of sports and entertainment products grew significantly, with a 22.2% year-on-year increase in the first half of 2025 [5] Industry Dynamics - The Chinese gold consumption in the first half of 2025 was 505.205 tons, a decrease of 3.54% year-on-year, with jewelry consumption dropping by 26% [5] - The pharmaceutical industry is seeing advancements in innovative drugs, particularly in obesity treatments with GLP-1 and Amylin therapies showing promising results in clinical trials [8][11] - In the biopharmaceutical sector, ADC drugs for lung cancer are demonstrating significant efficacy, with several products showing improved outcomes in clinical trials [10][12]

Core Insights - The report highlights the strong performance of the U.S. job market, with June non-farm employment data showing an increase of 147,000 jobs and a decrease in the unemployment rate from 4.2% to 4.1% [4] - The report notes the significant growth of the jewelry brand Zhou Li Fu, which went public on the Hong Kong Stock Exchange, raising approximately HKD 1.292 billion [5][6] - The report discusses the rapid expansion of 361 Degrees, which opened 49 new stores, establishing itself as a new landmark in urban sports consumption [6][7] Market Trends - The U.S. economy is experiencing a mild cooling phase, with concerns about the job market being alleviated by strong employment data [4] - The textile and apparel sector saw a 1.36% increase, while the light industry manufacturing sector rose by 0.58% [6] - The gold and jewelry retail sector reported a year-on-year growth of 21.8% in May, indicating a robust demand for gold and jewelry products [7] Company Performance - Zhou Li Fu's revenue is projected to grow from CNY 3.102 billion in 2022 to CNY 5.718 billion in 2024, with a compound annual growth rate (CAGR) of 35.8% [5] - The net profit of Zhou Li Fu is expected to increase from CNY 575 million in 2022 to CNY 706 million in 2024, with a CAGR of 10.8% [5] - Tao Tao Vehicle's net profit for the first half of 2025 is projected to be between CNY 310 million and CNY 360 million, representing a year-on-year growth of 70.34% to 97.81% [14][16] Industry Developments - The global regulatory framework for stablecoins is advancing, with significant legislative actions in the U.S., EU, and Hong Kong [9][10] - The report emphasizes the entry of traditional financial institutions and tech giants into the stablecoin market, enhancing the ecosystem [9] - The report also highlights the potential for Real World Assets (RWA) to create new growth opportunities for stablecoins [10] Investment Recommendations - The report recommends focusing on companies with strong mid-year performance, particularly in the textile and apparel sector, such as Anta Sports and 361 Degrees [6][7] - In the gold and jewelry sector, companies like Lao Pu Gold and Chao Hong Ji are highlighted as having strong mid-year performance potential [7] - The report suggests monitoring the progress of virtual asset licensing in Hong Kong and the core application scenarios for stablecoins in the long term [12]

Investment Rating - The industry rating is neutral for the biopharmaceutical sector and other pharmaceutical sectors [3] Core Insights - Samsung Biologics reported a strong performance in Q1 2025, achieving revenue of 12,980 billion KRW, a year-on-year increase of 37.06%, and a net profit of 3,760 billion KRW, up 110.06% [4][8] - The company maintains its full-year guidance for 2025, expecting revenue growth of 20%-25%, primarily driven by the stable operation of its fourth factory [8] - The growth in Q1 2025 was attributed to the steady operation of the fourth factory, increased sales of biosimilar products, and foreign exchange gains [8] Summary by Sections Financial Performance - In Q1 2025, Samsung Biologics reported an EBITDA of 6,500 billion KRW, reflecting a year-on-year growth of 78.08% [8] - The gross profit for the same period was 7,330 billion KRW, marking a 74.52% increase year-on-year [8] - As of Q1 2025, the company had current assets of 52,630 billion KRW and non-current assets of 121,740 billion KRW, with current liabilities of 36,190 billion KRW and non-current liabilities of 25,380 billion KRW [8] Performance Guidance - The company expresses confidence in achieving its previously set performance guidance for 2025 despite uncertainties in the macroeconomic environment [8] - The company is closely monitoring tariff changes in the U.S. pharmaceutical industry and is prepared to respond accordingly [8]